An Houston doctor announced Monday that she plans to sue Houston Methodist hospital, saying the medical center has refused to respond to her Freedom of Information Act (FOIA) requests for COVID-19 data. Doctor Mary Bowden, an ear, nose and throat specialist, said she is also seeking financial information from the hospital, including the possible bonuses it has received for using the potentially toxic drug remdesivir to treat COVID patients.
Bowden was thrust into the spotlight last November after the hospital suspended her privileges due to her views on vaccines and early treatment for the coronavirus.
She had just recently joined the staff at Houston Methodist, according to Click2Houston. Bowden runs her own private practice, and is a member of the Front Line COVID-19 Critical Care Alliance (FlCCC).
The doctor, who claims she has treated more than 2,000 patients with COVID-19, said she had a great relationship with Methodist until they disagreed with some of her social media posts regarding vaccine mandates and treatments.
“The issues with vaccines and ivermectin really go against patient autonomy and their right to choose their treatment,” Dr. Bowden said.
She told KPRC in a previous interview that people are being discriminated against because they have not been vaccinated.
“I am not intimidated by the bullying,” said Dr. Bowden. “I am just trying to save the lives of my patients.”
During a press conference in front of Houston Methodist, Bowden said the hospital has chosen “secrecy over transparency.”
“I have made formal requests [for data] and received nothing,” she said.
The doctor listed a number of pointed questions she would like the hospital to disclose, including how many people vaccinated through the hospital have had adverse reactions, and how many recent admissions of COVID-positive patients were fully vaccinated. Additionally, Bowden said wants to know how many fully vaccinated employees have suffered breakthrough cases, and how many of the 2,879 patients who died of COVID at the hospital were denied early treatments.
Bowden said she would also like answers to a number of financial questions to determine how much the hospital profited off of COVID, including how much has it been awarded to administer the controversial drug remdesivir to patients.
The data show that remdesivir does little to nothing to help COVID patients who are sick enough to be in the hospital, and has actually been the cause of acute renal failure, liver damage, and other adverse effects in patients.
In November of 2020, one month after the Food and Drug Administration (FDA) approved of remdesivir to treat COVID patients over 12, the World Health Organization (WHO) said the drug should not be used as treatment for hospitalized Covid-19 patients.
The medical establishment’s embrace of the toxic drug is suspicious for several reasons, the Blaze’s Daniel Horowitz reported.
On Feb. 5, Reuters reported that none other than the Wuhan Institute of Virology of the China Academy of Sciences sought a patent on Gilead’s remdesivir, a failed drug repurposed from treatment of Ebola, based on the alleged improvement of a single individual COVID patient reported in the New England Journal of Medicine.
Incidentally, remdesivir was developed by Dr. Ralph Baric’s lab at UNC Chapel Hill, the same lab that applied for the coronavirus spike protein gain-of-function research and is suspected by many to be behind the creation of this virus.
Dr. Anthony Fauci announced on April 29, 2020 that the proven failure would become the standard of care. He cited Gilead’s March 2020 study “of 53 coronavirus patients in the U.S. Canada, Europe, and Japan who used remdesivir for 10 days.”
The results, however, were the opposite of promising.
Sixty percent reported adverse events and 23 percent reported serious adverse events, the most common being “multiple-organ-dysfunction syndrome, septic shock, acute kidney injury, and hypotension.” Furthermore, “Four patients (8 percent) discontinued remdesivir treatment prematurely: one because of worsening of preexisting renal failure, one because of multiple organ failure, and two because of elevated aminotransferases, including one patient with a maculopapular rash.”
“Studies show that 71–75 percent of patients suffer an adverse effect, and the drug often had to be stopped after five to ten days because of these effects, such as kidney and liver damage, and death,” the Association of American Physicians and Surgeons (AAPS) reported in November.
But because hospitals are given financial incentives to use remdesivir, it is the drug of choice in most hospitals throughout the United States.
“The CARES Act provides incentives for hospitals to use treatments dictated solely by the federal government under the auspices of the NIH,” AAPS explained.
The hospital payments include:
A “free” required PCR test in the Emergency Room or upon admission for every patient, with government-paid fee to hospital.
Added bonus payment for each positive COVID-19 diagnosis.
Another bonus for a COVID-19 admission to the hospital.
A 20 percent “boost” bonus payment from Medicare on the entire hospital bill for use of remdesivir instead of medicines such as Ivermectin.
Another and larger bonus payment to the hospital if a COVID-19 patient is mechanically ventilated.
More money to the hospital if cause of death is listed as COVID-19, even if patient did not die directly of COVID-19.
A COVID-19 diagnosis also provides extra payments to coroners.
At a COVID Summit in Nashville, Tenn. last month, FLCCC founder Dr. Paul Marik said “The hospital gets a 20 percent bonus on the ENTIRE HOSPITAL BILL if they prescribe remdesivir.”
“So not only does the company get $3,000 to prescribe this drug, the hospital then gets a bonus for prescribing or using a toxic medication on patients which increases their risk of complications and death,” Marik continued. “A 20 percent bonus. Is this not evilness in its purest form?”